Literature DB >> 21741004

Reversal of hypolipidemia in chronic hepatitis C patients after successful antiviral therapy.

Yuan-Hung Kuo1, Tang-Wei Chuang, Chao-Hung Hung, Chien-Hung Chen, Jing-Houng Wang, Tsung-Hui Hu, Sheng-Nan Lu, Chuan-Mo Lee.   

Abstract

BACKGROUND/
PURPOSE: Chronic infection with the hepatitis C virus (HCV) is associated with impaired lipid metabolism. The aim of this study was to determine the impact of antiviral response on the serial change of serum lipids in chronic HCV patients.
METHODS: A total of 165 consecutive patients with HCV infection were prospectively enrolled. Serum total cholesterol (TC) and triglyceride (TG) levels in these subjects were compared with age, sex and body mass index-matched healthy individuals and 55 patients with chronic infection with hepatitis B virus (HBV). Serum lipid levels were measured in 143 patients with chronic HCV infection receiving pegylated interferon plus ribavirin therapy at baseline, at the end of treatment, and at week 24 after the end of treatment.
RESULTS: Patients with chronic HCV infection had significantly lower total TC and TG levels than normal controls (both p < 0.001). Serum TC levels were lower in HCV patients than in those infected with HBV (p < 0.001). Pretreatment serum lipid levels were not independent factors associated with sustained virological response (SVR). Among patients achieving a SVR, serum TC and TG levels significantly increased from 165 ± 30 mg/dL and 100 ± 47 mg/dL at baseline to 191 ± 36 mg/dL (p < 0.001) and 116 ± 77 mg/dL (p = 0.029) at week 24 posttreatment, whereas no evident change in lipid profile occurred in the non-SVR group.
CONCLUSION: Our data suggest that chronic HCV infection is associated with hypocholesterolemia and hypotriglyceridemia, which can be reversed by successful eradication of HCV. The clinical significance of hypolipidemia reversal among SVR patients, such as the risk of coronary artery or cerebral vascular disease, should be further investigated.
Copyright © 2011 Formosan Medical Association & Elsevier. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21741004     DOI: 10.1016/S0929-6646(11)60054-5

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  13 in total

1.  Effect of sofosbuvir and daclatasvir on lipid profile, glycemic control and quality of life index in chronic hepatitis C, genotype 3 patients.

Authors:  Ayush Jain; Bhupinder Singh Kalra; Siddharth Srivastava; Shalini Chawla
Journal:  Indian J Gastroenterol       Date:  2019-02-02

Review 2.  Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen.

Authors:  Amedeo Lonardo; Luigi Elio Adinolfi; Luciano Restivo; Stefano Ballestri; Dante Romagnoli; Enrica Baldelli; Fabio Nascimbeni; Paola Loria
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

3.  Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in Hepatitis C virus/HIV-coinfected persons: the AIDS Clinical Trials Group A5178 Study.

Authors:  Adeel A Butt; Triin Umbleja; Janet W Andersen; Kenneth E Sherman; Raymond T Chung
Journal:  Clin Infect Dis       Date:  2012-05-04       Impact factor: 9.079

4.  The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients.

Authors:  Hee Jae Jung; Young Seok Kim; Sang Gyune Kim; Yun Nah Lee; Soung Won Jeong; Jae Young Jang; Sae Hwan Lee; Hong Soo Kim; Boo Sung Kim
Journal:  Clin Mol Hepatol       Date:  2014-03-26

5.  Distinct patterns of the lipid alterations between genotype 1 and 2 chronic hepatitis C patients after viral clearance.

Authors:  Ming-Ling Chang; Yung-Kuan Tsou; Tsung-Hui Hu; Cheng-Hui Lin; Wey-Ran Lin; Chang-Mu Sung; Tsung-Hsing Chen; Mei-Ling Cheng; Kuo-Chin Chang; Cheng-Tang Chiu; Chau-Ting Yeh; Jong-Hwei Su Pang; Ming-Shi Shiao
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

6.  Retrospective study of the associations between hepatitis C virus infection and metabolic factors.

Authors:  Shira Yair-Sabag; Elchanan Nussinson; Ofir Ben-Assuli; Fahmi Shibli; Azmi Shahbari; Shira Zelber-Sagi
Journal:  World J Hepatol       Date:  2016-10-28

7.  Hepatitis C eradication with sofosbuvir leads to significant metabolic changes.

Authors:  Amilcar L Morales; Zachary Junga; Manish B Singla; Maria Sjogren; Dawn Torres
Journal:  World J Hepatol       Date:  2016-12-18

8.  Association between phase angle, anthropometric measurements, and lipid profile in HCV-infected patients.

Authors:  Mariana de Souza Dorna; Nara Aline Costa; Erick Prado de Oliveira; Ligia Yukie Sassaki; Fernando Gomes Romeiro; Sergio Alberto Rupp de Paiva; Marcos Ferreira Minicucci; Giovanni Faria Silva
Journal:  Clinics (Sao Paulo)       Date:  2013-12       Impact factor: 2.365

9.  Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment.

Authors:  Satoru Hashimoto; Hiroshi Yatsuhashi; Seigo Abiru; Kazumi Yamasaki; Atsumasa Komori; Shinya Nagaoka; Akira Saeki; Shinjiro Uchida; Shigemune Bekki; Yuki Kugiyama; Kazuyoshi Nagata; Minoru Nakamura; Kiyoshi Migita; Kazuhiko Nakao
Journal:  PLoS One       Date:  2016-09-28       Impact factor: 3.240

10.  Direct-acting antiviral agents against hepatitis C virus and lipid metabolism.

Authors:  Tatsuo Kanda; Mitsuhiko Moriyama
Journal:  World J Gastroenterol       Date:  2017-08-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.